What happens when drug discovery leaders, big pharma, regulators, AI solution providers, and venture capital sit in the same room? Bryden Wood's Accelerate roundtable on AI and pharmaceutical manufacturing surfaced a clear consensus: the hype is in the wrong places – and we are not ambitious enough.

Professor John Dyson builds an economic model to test what happens when pharmaceutical production scale gets it wrong. The results are striking – and largely ignored by industry. Understanding diseconomies of scale, he argues, could save billions and change how companies think about their entire product portfolio.

Solvents are costly, environmentally harmful, and heavily regulated – yet the pharmaceutical industry has no clear path to replacing them. This roundtable report from Bryden Wood's Accelerate Pharmaceuticals series captures what happens when the whole ecosystem comes together to confront the dilemma honestly.

Why are things the size they are? Professor John Dyson traces the logic of scale from mitochondria to mega-factories – and argues that nature solved this problem millions of years ago. The question is whether industry is paying attention.

Two very different projects. Two FOYA awards. One unifying approach. Adam Jordan examines how Design to Value delivered award-winning outcomes for GSK in Parma and Pfizer in Singapore – and what both projects reveal about the gap between conventional briefing and genuinely value-led design.

Laboratories underpin everything from cancer research to vaccine development – yet they remain largely invisible in conversations about industrial transformation. Bryden Wood convened leaders from across the sector to ask what the laboratory of the future looks like, and what it will take to get there.

How do you stop a great pharmaceutical project concept from being ground down by the delivery process? In Part 2 of Pharma's Conundrum, Professor John Dyson sets out the principles of Integrated Project Delivery – and why shared value, not scope management, is the real measure of success.

The pharmaceutical industry assumes that once a project concept is agreed, iteration is a risk. Professor John Dyson argues the opposite – that emergence in design is inevitable, and that pretending otherwise destroys value. Part one of his Pharma's Conundrum series sets out a smarter approach to scheme design.

Process intensification, modularity, and automation could deliver billions in improved cash flow and drive pharmaceutical manufacturing close to net zero. So why isn't the industry moving faster? Professor John Dyson reports on what happened when four of the world's largest pharma companies came together to ask that question out loud.

Place matters more than most people think. Professor John Dyson argues that the environment where collaboration happens – its architecture, aesthetics, and culture – carries far more weight than the agenda. The Grand Hotel of Value is his answer to a problem the pharmaceutical industry hasn't yet named.

Small molecule APIs account for three quarters of new pharmaceutical products and make up most of the WHO's essential medicines list. Yet the factories that produce them haven't fundamentally changed in decades. Adrian La Porta sets out the case for a new manufacturing paradigm – built on miniaturisation, process intensification, automation, and systemisation.

The Devil's Snare binds tighter the more you struggle. Professor John Dyson argues this is precisely what the construction and pharmaceutical industries are doing – and that the way out is not more effort in the same direction but the courage to try something genuinely different.